# Healthy lifestyle factors and recurrent cardiovascular events in patients with OSA: the SAVE study.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12306100</article-id><article-id pub-id-type="pmid">40721783</article-id>
<article-id pub-id-type="publisher-id">4279</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04279-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Healthy lifestyle factors and recurrent cardiovascular events in patients with OSA: the SAVE study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>You</surname><given-names>Shoujiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zheng</surname><given-names>Danni</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Loffler</surname><given-names>Kelly A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>McEvoy</surname><given-names>R. Doug</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Qiang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Yuanming</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barb&#x000e9;</surname><given-names>Ferran</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ou</surname><given-names>Qiong</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chun-feng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Yongjun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lorenzi-Filho</surname><given-names>Geraldo</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Tripathi</surname><given-names>Manjari</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Anderson</surname><given-names>Craig S.</given-names></name><address><email>canderson@georgeinstitute.org.au</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><collab>for the SAVE Investigators</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xjrkt08</institution-id><institution-id institution-id-type="GRID">grid.452666.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 8363</institution-id><institution>Department of Neurology and Clinical Research Center of Neurological Disease, </institution><institution>The Second Affiliated Hospital of SooChow University, </institution></institution-wrap>Suzhou, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03r8z3t63</institution-id><institution-id institution-id-type="GRID">grid.1005.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 4902 0432</institution-id><institution>The George Institute for Global Health, Faculty of Medicine, </institution><institution>University of New South Wales, </institution></institution-wrap>Missenden Road, PO Box M201, Sydney, NSW 2050 Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kpzv902</institution-id><institution-id institution-id-type="GRID">grid.1014.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0367 2697</institution-id><institution>Flinders Health and Medical Research Institute, College of Medicine and Public Health,, </institution><institution>Flinders University, </institution></institution-wrap>Adelaide, Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04hja5e04</institution-id><institution-id institution-id-type="GRID">grid.508194.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 7885 9333</institution-id><institution>The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, </institution></institution-wrap>Guangzhou, People&#x02019;s Republic of China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0119pby33</institution-id><institution-id institution-id-type="GRID">grid.512891.6</institution-id><institution>Respiratory Department, Centro de Investigacio&#x000b4;n Biome&#x000b4;dica en Red de Enfermedades Respiratorias, Institutde Recerca Biome`dica de Lleida, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff6"><label>6</label>Sleep Center, Respiratory and Critical Medical Department, Guangdong Geriatric Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510000 People&#x02019;s Republic of China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xjrkt08</institution-id><institution-id institution-id-type="GRID">grid.452666.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 8363</institution-id><institution>Department of Respiratory, The Second Affiliated Hospital of Soochow University, </institution></institution-wrap>Suzhou, China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036rp1748</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution>Instituto do Coracao (Incor) and Hospital Universitario, </institution></institution-wrap>Sao Paulo, Brazil </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02dwcqs71</institution-id><institution-id institution-id-type="GRID">grid.413618.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 6103</institution-id><institution>Neurology Department, All India Institute of Medical Sciences, </institution></institution-wrap>Delhi, India </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013q1eq08</institution-id><institution-id institution-id-type="GRID">grid.8547.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0125 2443</institution-id><institution>The Institute of Science and Technology for Brain-inspired Research, </institution><institution> Fudan University, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gpvde20</institution-id><institution-id institution-id-type="GRID">grid.413249.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0385 0051</institution-id><institution>Neurology Department, Royal Prince Alfred Hospital, </institution></institution-wrap>Sydney, Australia </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>442</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The extent to which healthy lifestyle factors influence recurrent cardiovascular events in obstructive sleep apnea (OSA) patients is uncertain. To evaluate the association between adherence to baseline healthy lifestyle and the risk of recurrent cardiovascular events in OSA patients.</p></sec><sec><title>Methods</title><p id="Par2">Post hoc analyses of the Sleep Apnea Cardiovascular Endpoints (SAVE) study involving participants with moderate-to-severe OSA and established cardiovascular disease (CVD) who were randomized to continuous positive airway pressure (CPAP) plus usual care or usual care alone. We assigned a score ranging from 0 to 4 for each participant, based on the number of criteria met for the baseline health lifestyle factors of non-smoking, moderate-to-vigorous physical activity, ideal waist/hip ratio, and low-to-moderate alcohol consumption.</p></sec><sec><title>Results</title><p id="Par3">In total, 2659 OSA patients with established CVD were included. The adjusted hazard ratios for participants with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors compared with none were 0.64 (95% confidence interval [CI] 0.50&#x02013;0.84) for composite cardiovascular events, 0.46 (0.28&#x02013;0.74) for stroke, 0.65 (0.45&#x02013;0.96) for hospitalization for unstable angina, 0.35 (0.19&#x02013;0.63) for all-cause mortality, and 0.36 (0.16&#x02013;0.79) for CVD death during a mean follow-up of 3.7&#x000a0;years. Each increment in healthy lifestyle factor score was associated with reduced risk of composite and separate cardiovascular events. A trend was found showing greater CPAP treatment benefit in those with more baseline healthy lifestyle for myocardial infarction and all-cause mortality; however, it did not reach statistical significance.</p></sec><sec><title>Conclusions</title><p id="Par4">Greater adherence to an overall baseline healthy lifestyle is significantly associated with a lower risk of recurrent composite cardiovascular events in OSA patients with established CVD.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04279-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Obstructive sleep apnea</kwd><kwd>SAVE</kwd><kwd>Healthy lifestyle factors</kwd><kwd>Recurrent cardiovascular events</kwd><kwd>Predict</kwd></kwd-group><funding-group><award-group><funding-source><institution>the National Health and Medical Research Council (NHMRC) of Australia</institution></funding-source><award-id>1006501 and 1060078</award-id><award-id>1006501 and 1060078</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Fisher &#x00026; Paykel Healthcare, the Australasian Sleep Trials Network</institution></funding-source><award-id>343020</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>the Spanish Respiratory Society</institution></funding-source><award-id>105-2011</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Fondo de Investigaciones Sanitarias</institution></funding-source><award-id>13/02053</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par16">Obstructive sleep apnea (OSA), characterized by recurrent episodes of upper airway obstruction and intermittent hypoxemia [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], is common in people with cardiovascular disease (CVD) [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>] and increases the risk of recurrent CVD events [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, effective interventions to reduce CVD risk are crucial in patients with co-occurring OSA and CVD. The unhealthy lifestyle factors of smoking, poor diet, sedentary activity, and obesity are common risk factors shared between OSA and CVD [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Meanwhile, some studies suggest that weight loss and lifestyle interventions are significantly associated with a decrease in OSA severity [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, studies indicate that adherence to an overall healthy lifestyle is associated with a dose-dependent reduction in the risk of CVD in the general population and in those with diabetes mellitus [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. No specific data exists on the relationship between healthy lifestyle factors and recurrent cardiovascular events in adults with co-occurring OSA and established CVD.
</p><p id="Par17">The international Sleep Apnea Cardiovascular Endpoints (SAVE) trial showed that the provision of standard OSA treatment with continuous positive airway pressure (CPAP) on top of usual care does not prevent major cardiovascular events in patients with OSA and coronary or cerebrovascular disease [<xref ref-type="bibr" rid="CR19">19</xref>]. Whether adherence to an overall healthy lifestyle can modify the effects of CPAP in these participants is uncertain. Herein, we report post hoc analysis of the SAVE database to determine associations of adherence to overall baseline healthy lifestyle factors and the risk of the primary endpoint, a composite of major cardiovascular events, and the individual components, and whether overall baseline healthy lifestyle factors could modify the impact of CPAP treatment on these outcomes.
</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par18">SAVE was an international, multicenter, randomized, parallel-group, open-label, blinded endpoint assessed clinical trial that determined the effectiveness of CPAP on top of standard of care versus standard of care alone, to reduce recurrent CVD events in high-risk adults with OSA [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In brief, a total of 2687 adults (age 45 to 75&#x000a0;years) with a diagnosis of moderate-to-severe OSA and established coronary artery disease and/or cerebrovascular disease were randomized to receive CPAP plus usual care or usual care alone at 89 clinical centers in 7 countries from December 2008 to November 2013. The diagnosis of OSA was based on a moderate to high oxygen desaturation index (ODI,&#x02009;&#x02265;&#x02009;12 events per hour with&#x02009;&#x02265;&#x02009;4% oxygen saturation dip), established using a home sleep screening device (ApneaLink, ResMed) that was confirmed centrally by sleep specialists. People were excluded if they had severe daytime sleepiness (Epworth sleepiness scale [ESS] score&#x02009;&#x0003e;&#x02009;15), very severe nocturnal hypoxemia (oxygen saturation&#x02009;&#x0003c;&#x02009;80% for&#x02009;&#x0003e;&#x02009;10% of the monitoring time), or a predominantly Cheyne-Stokes respiration pattern. The trial is registered at ClinicalTrials.gov (NCT00738179).</p></sec><sec id="Sec4"><title>Definition of healthy lifestyle factors</title><p id="Par19">Four key lifestyle factors were considered at study baseline: smoking status, alcohol consumption status, level of physical activity, and waist/hip ratio (WHR), extracted from the SAVE database. Healthy lifestyle factors were defined as having the folowing: (i) never smoked [<xref ref-type="bibr" rid="CR21">21</xref>]; (ii) a moderate to vigorous level of physical activity (self-reported moderate or vigorous exercise of&#x02009;&#x0003e;&#x02009;15&#x000a0;min duration at least once per week) [<xref ref-type="bibr" rid="CR22">22</xref>]; (iii) low to moderate alcohol consumption (&#x02264;&#x02009;21 self-reported weekly standard drinks for men,&#x02009;&#x02264;&#x02009;14 for women) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]; and (iv) an ideal WHR (&#x0003c;&#x02009;0.9&#x000a0;cm/cm in men,&#x02009;&#x0003c;&#x02009;0.85&#x000a0;cm/cm in women [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] calculated from clinic measurements). A total score for adherence to healthy lifestyle factors was calculated, whereby 1 point was allocated for each individual factor, such that the total score ranged from 0 to 4. Thus, a higher score indicates greater adherence to healthy lifestyle factors.</p></sec><sec id="Sec5"><title>Outcomes</title><p id="Par20">The primary outcome was a composite of cardiovascular events of death from any CVD cause, myocardial infarction (including silent myocardial infarction), stroke, hospitalization for heart failure, acute coronary syndrome (including unstable angina), or transient ischemic attack (TIA). Secondary outcomes included stroke alone, myocardial infarction alone, hospitalization for unstable angina, all-cause mortality, death from any cardiovascular cause (CVD death), TIA, composite of cerebral events, composite of cardiac events, and revascularization procedures [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par21">Participants were categorized based on their overall healthy lifestyle factors score (0, 1, and&#x02009;&#x02265;&#x02009;2) to create three groups with suitable sizes to facilitate statistical comparison. Comparisons of baseline characteristics across categories were made using variance, Wilcoxon rank-sum, or chi-squared tests, as appropriate. Cumulative incidence rates of study outcomes across categories (0, 1, and&#x02009;&#x02265;&#x02009;2 overall healthy lifestyle factors) were estimated using Kaplan&#x02013;Meier curves and compared using log-rank tests. Associations between each healthy lifestyle factor and overall healthy lifestyle score and primary outcome, and overall healthy lifestyle score and secondary outcomes, were assessed in Cox proportional hazards models. Based on established clinical relevance, availability in the dataset, prior literature, and differences in baseline characteristics, we built two Cox proportional hazards models: model 1 was adjusted for age, sex, region (non-Asian vs. Asian), and CPAP allocation; model 2 was further adjusted for history of coronary artery disease, history of cerebrovascular disease, history of hypertension, known diagnosis of diabetes, baseline neck circumference, baseline antihypertensives use, baseline statin or other antilipidemic agents use, baseline antidiabetic oral medication or insulin use, baseline aspirin or other antithrombotic agents use, and ODI (a causal directed acyclic graph is provided in Additional file 1: Figure S1). Hazard ratios (HR) and 95% confidence intervals (CI) for the three categories of overall healthy lifestyle scores and per each increment of overall healthy lifestyle score were calculated. Absolute risk reductions with 95% CIs were also reported for patients with 1 and&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors, compared to those with none.</p><p id="Par22">We tested for homogeneity in effects of CPAP treatment (compared to usual care) and good CPAP adherence (average&#x02009;&#x02265;&#x02009;4&#x000a0;h per night during the study) by overall baseline healthy lifestyle factors on primary and secondary outcomes by adding interaction terms in the Cox regression models. To assess the robustness of the association between overall baseline healthy lifestyle factors and the primary outcome, subgroup analyses were conducted in multivariable-adjusted models stratified by age (&#x02265;&#x02009;61 vs.&#x02009;&#x0003c;&#x02009;61&#x000a0;years), sex, region (Asian vs. non-Asian), history of coronary artery disease, history of cerebrovascular disease, apnea&#x02013;hypopnea index (AHI) (&#x02265;&#x02009;30 vs.&#x02009;&#x0003c;&#x02009;30 events/hour), ODI (&#x02265;&#x02009;24 vs.&#x02009;&#x0003c;&#x02009;24 events/hour), body-mass index (BMI,&#x02009;&#x02264;&#x02009;30 vs.&#x02009;&#x0003e;&#x02009;30&#x000a0;kg/m<sup>2</sup>) and ESS score (0&#x02013;9 vs. 10&#x02013;15). All analyses were performed with Stata 17.0 (Stata Corp, College Station, TX, USA).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Clinical characteristics of the study cohort</title><p id="Par23">Of the 2687 SAVE participants, a total of 2659 (mean age 61.2 [7.8] years; 509 [19.1%] female; mean AHI 29.2 [16.2]) with available data were included in this study (participant flow shown in Additional file 1: Figure S2). The median (IQR) of overall baseline healthy lifestyle factors was 1 (1&#x02013;2) and their distribution is shown in Additional file 1: Figure S3. Only 173 (6.5%) patients had 3 or 4 healthy lifestyle factors at baseline. Table <xref rid="Tab1" ref-type="table">1</xref> outlines the baseline characteristics of participants according to overall healthy lifestyle score. In comparison to participants with lower healthy lifestyle scores, those with higher scores tended to be older, female and with cerebrovascular disease, fewer co-morbidities of coronary artery disease, hypertension, diabetes, and coronary revascularization, and lower prior drug treatment with antihypertensive, statin or other lipid&#x02011;lowering agents, antidiabetic oral medication or insulin, and aspirin or other antithrombotic agents. Patients with higher healthy lifestyle scores also had lower BMI, and waist and neck circumferences, than those with less healthy lifestyles. There were no significant differences in AHI, ODI, and ESS scores across the various healthy lifestyle factor groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of participants according to numbers of overall healthy lifestyle factors in SAVE</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" rowspan="2">Total</th><th align="left" colspan="4">Numbers of overall healthy lifestyle factors&#x000a0;</th></tr><tr><th align="left">0</th><th align="left">1</th><th align="left">&#x02265;&#x02009;2</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">No. of patients</td><td align="left">2659</td><td align="left">590</td><td align="left">1171</td><td align="left">898</td><td align="left"/></tr><tr><td align="left">Age, y</td><td align="left">61.2 (7.8)</td><td align="left">60.6 (7.3)</td><td align="left">61.6 (7.9)</td><td align="left">61.1 (8.0)</td><td align="left">0.041</td></tr><tr><td align="left">Female sex, <italic>n</italic> (%)</td><td align="left">509 (19.1)</td><td align="left">71 (12.0)</td><td align="left">261 (22.3)</td><td align="left">177 (19.7)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Residence in Asia, <italic>n</italic> (%)</td><td align="left">1678 (63.1)</td><td align="left">352 (59.7)</td><td align="left">751 (64.2)</td><td align="left">575 (64.0)</td><td align="left">0.14</td></tr><tr><td align="left" colspan="6"><bold>Medical and lifestyle history</bold></td></tr><tr><td align="left">&#x02009;Hypertension</td><td align="left">2084 (78.4)</td><td align="left">479 (81.2)</td><td align="left">935 (79.8)</td><td align="left">670 (74.6)</td><td align="left">0.003</td></tr><tr><td align="left">&#x02009;Diabetes</td><td align="left">790 (29.7)</td><td align="left">216 (36.6)</td><td align="left">381 (32.5)</td><td align="left">193 (21.5)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Coronary artery disease</td><td align="left">1456 (54.8)</td><td align="left">353 (59.8)</td><td align="left">637 (54.4)</td><td align="left">466 (51.9)</td><td align="left">0.010</td></tr><tr><td align="left">&#x02009;Cerebrovascular disease</td><td align="left">1311 (49.3)</td><td align="left">264 (44.7)</td><td align="left">582 (49.7)</td><td align="left">465 (51.8)</td><td align="left">0.028</td></tr><tr><td align="left">&#x02009;Any stroke</td><td align="left">1171 (44.0)</td><td align="left">240 (40.7)</td><td align="left">541 (46.2)</td><td align="left">390 (43.4)</td><td align="left">0.080</td></tr><tr><td align="left">&#x02009;Any transient ischemic attack</td><td align="left">265 (10.0)</td><td align="left">51 (8.6)</td><td align="left">99 (8.5)</td><td align="left">115 (12.8)</td><td align="left">0.002</td></tr><tr><td align="left">&#x02009;Any heart disease</td><td align="left">1077 (40.5)</td><td align="left">250 (42.4)</td><td align="left">469 (40.1)</td><td align="left">358 (39.9)</td><td align="left">0.58</td></tr><tr><td align="left">&#x02009;Myocardial infarction</td><td align="left">891 (33.5)</td><td align="left">240 (40.7)</td><td align="left">397 (33.9)</td><td align="left">254 (28.3)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Coronary revascularization</td><td align="left">902 (33.9)</td><td align="left">229 (38.8)</td><td align="left">394 (33.6)</td><td align="left">279 (31.1)</td><td align="left">0.008</td></tr><tr><td align="left">&#x02009;Coronary&#x02011;artery bypass surgery</td><td align="left">316 (11.9)</td><td align="left">74 (12.5)</td><td align="left">142 (12.1)</td><td align="left">100 (11.1)</td><td align="left">0.67</td></tr><tr><td align="left">&#x02009;Heart failure</td><td align="left">50 (1.9)</td><td align="left">13 (2.2)</td><td align="left">25 (2.1)</td><td align="left">12 (1.3)</td><td align="left">0.34</td></tr><tr><td align="left">&#x02009;Never smoker</td><td align="left">1174 (44.2)</td><td align="left">0 (0.0)</td><td align="left">565 (48.2)</td><td align="left">609 (67.8)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Low to moderate alcohol drinking</td><td align="left">612 (23.0)</td><td align="left">0 (0.0)</td><td align="left">228 (19.5)</td><td align="left">384 (42.8)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Moderate to vigorous physical activity</td><td align="left">972 (36.6)</td><td align="left">0 (0.0)</td><td align="left">304 (26.0)</td><td align="left">668 (74.4)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Body-mass index, kg/m<sup>2</sup></td><td align="left">28.7 (4.5)</td><td align="left">29.5 (4.8)</td><td align="left">28.9 (4.5)</td><td align="left">27.8 (4.2)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Waist measurement (cm)</td><td align="left">101.0 (12.2)</td><td align="left">104.2 (11.5)</td><td align="left">101.6 (11.6)</td><td align="left">98.0 (12.7)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Waist/hip ratio (cm/cm)</td><td align="left">1.0 (0.1)</td><td align="left">1.0 (0.1)</td><td align="left">1.0 (0.1)</td><td align="left">0.9 (0.1)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Neck circumference</td><td align="left">40.7 (4.1)</td><td align="left">41.5 (3.7)</td><td align="left">40.7 (4.0)</td><td align="left">40.2 (4.3)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="6"><bold>Cardiovascular factors</bold></td></tr><tr><td align="left">&#x02009;Systolic BP, mm Hg</td><td align="left">131.2 (16.1)</td><td align="left">130.8 (16.8)</td><td align="left">131.6 (16.3)</td><td align="left">131.0 (15.2)</td><td align="left">0.55</td></tr><tr><td align="left">&#x02009;Diastolic BP, mm Hg</td><td align="left">79.6 (10.7)</td><td align="left">79.4 (11.1)</td><td align="left">79.3 (11.1)</td><td align="left">80.2 (10.0)</td><td align="left">0.18</td></tr><tr><td align="left">&#x02009;Heart rate, bpm</td><td align="left">71.2 (11.3)</td><td align="left">70.8 (11.7)</td><td align="left">71.2 (11.0)</td><td align="left">71.5 (11.3)</td><td align="left">0.55</td></tr><tr><td align="left" colspan="6"><bold>Obstructive sleep apnea characteristics</bold></td></tr><tr><td align="left">&#x02009;Oxygen desaturation index</td><td align="left">28.2 (14.3)</td><td align="left">28.4 (14.4)</td><td align="left">28.7 (14.3)</td><td align="left">27.4 (14.1)</td><td align="left">0.097</td></tr><tr><td align="left">&#x02009;Apnea&#x02013;hypopnea index</td><td align="left">29.2 (16.2)</td><td align="left">29.1 (16.1)</td><td align="left">29.5 (16.2)</td><td align="left">28.9 (16.2)</td><td align="left">0.69</td></tr><tr><td align="left">&#x02009;Epworth Sleepiness Scale score</td><td align="left">7.4 (3.6)</td><td align="left">7.5 (3.8)</td><td align="left">7.4 (3.6)</td><td align="left">7.3 (3.5)</td><td align="left">0.34</td></tr><tr><td align="left" colspan="6"><bold>Randomized treatments</bold></td></tr><tr><td align="left">&#x02009;CPAP treatment</td><td align="left">1331 (50.1)</td><td align="left">313 (53.1)</td><td align="left">576 (49.2)</td><td align="left">442 (49.2)</td><td align="left">0.26</td></tr><tr><td align="left" colspan="6"><bold>Prior use of medications</bold></td></tr><tr><td align="left">&#x02009;Antihypertensive agent</td><td align="left">2075 (78.0)</td><td align="left">472 (80.0)</td><td align="left">932 (79.6)</td><td align="left">671 (74.7)</td><td align="left">0.013</td></tr><tr><td align="left">&#x02009;Statin/other lipid-lowering agent</td><td align="left">1556 (58.5)</td><td align="left">389 (65.9)</td><td align="left">711 (60.7)</td><td align="left">456 (50.8)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Antidiabetic oral medication</td><td align="left">575 (21.6)</td><td align="left">160 (27.1)</td><td align="left">281 (24.0)</td><td align="left">134 (14.9)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02009;Any insulin</td><td align="left">163 (6.1)</td><td align="left">49 (8.3)</td><td align="left">72 (6.1)</td><td align="left">42 (4.7)</td><td align="left">0.017</td></tr><tr><td align="left">&#x02009;Aspirin/other antithrombotic agent</td><td align="left">2005 (75.4%)</td><td align="left">485 (82.2)</td><td align="left">914 (78.1)</td><td align="left">606 (67.5)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p>Values are mean (SD) for continuous variables, and number (%) for categorical variables</p><p><italic>BP</italic> indicates blood pressure; <italic>CPAP</italic> continuous positive airway pressure; <italic>SAVE</italic> Sleep Apnea Cardiovascular Endpoints</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Overall healthy lifestyle factors and composite cardiovascular events</title><p id="Par24">After a mean follow-up of 3.7&#x000a0;years, 432 primary composite cardiovascular events were observed (16.2% of participants). Associations of individual lifestyle factors and the primary outcome are shown in Additional file 1: Table S1. Moderate to vigorous physical activity (HR 0.71, 95%CI 0.58&#x02013;0.88) and low to moderate alcohol consumption (HR 0.73, 95% CI 0.57&#x02013;0.94) were independently associated with lower risk of composite cardiovascular events after adjustment for covariables. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A shows the Kaplan&#x02013;Meier curves for the primary outcome by overall healthy lifestyle factor score. Patients with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had significantly lower cumulative incidence of the primary outcome (log-rank <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Compared to participants without any healthy lifestyle factors, those with 1 and&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had 24% (HR 0.76, 95% CI 0.60&#x02013;0.96) and 36% (HR 0.64, 95%CI 0.50&#x02013;0.84) lower risk of composite cardiovascular events, respectively (<italic>P</italic> for trend&#x02009;=&#x02009;0.001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Moreover, adherence to healthy lifestyle factors was associated with a dose-dependent reduction in composite cardiovascular events; every unit increase in healthy lifestyle factor score was associated with a 19% (HR 0.81, 95% CI 0.72&#x02013;0.90) lower risk of composite cardiovascular events (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In addition, compared to participants with no healthy lifestyle factors, those with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had an absolute risk reduction of 7.2% (95% CI 3.2&#x02013;11.2%) for composite cardiovascular events (Additional file 1: Table S2).&#x000a0;<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Kaplan&#x02013;Meier curves&#x000a0;<bold>A</bold> Composite cardiovascular events; (<bold>B</bold>) stroke; (<bold>C</bold>) myocardial infarction; (<bold>D</bold>) hospitalization for unstable angina; (<bold>E</bold>) all-cause mortality; (<bold>F</bold>) CVD death. CVD indicates cardiovascular disease</p></caption><graphic xlink:href="12916_2025_4279_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>HRs (95% CIs) of composite cardiovascular events, stroke, myocardial infarction, hospitalization for unstable angina, all-cause mortality, and CVD death according to the overall healthy lifestyle factors in SAVE</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4"><bold>Numbers of overall healthy lifestyle factors</bold></th><th align="left" rowspan="2"><bold>Each unit increase in healthy </bold><bold>lifestyle factors</bold></th></tr><tr><th align="left">0</th><th align="left">1</th><th align="left"><bold>&#x02265;&#x02009;2</bold></th><th align="left"><italic>P</italic> trend</th></tr></thead><tbody><tr><td align="left" colspan="6"><bold>Composite cardiovascular events</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">122 (20.7)</td><td align="left">189 (16.1)</td><td align="left">121 (13.5)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.73 (0.58&#x02013;0.92)</td><td align="left">0.57 (0.44&#x02013;0.74)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">0.76 (0.68&#x02013;0.85)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.76 (0.60&#x02013;0.96)</td><td align="left">0.64 (0.50&#x02013;0.84)</td><td align="left">0.001</td><td align="left">0.81 (0.72&#x02013;0.90)</td></tr><tr><td align="left" colspan="6"><bold>Stroke</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">41 (7.0)</td><td align="left">62 (5.3)</td><td align="left">30 (3.3)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.69 (0.46&#x02013;1.03)</td><td align="left">0.42 (0.26&#x02013;0.68)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">0.66 (0.53&#x02013;0.82)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.71 (0.48&#x02013;1.07)</td><td align="left">0.46 (0.28&#x02013;0.74)</td><td align="left">0.002</td><td align="left">0.68 (0.55&#x02013;0.85)</td></tr><tr><td align="left" colspan="6"><bold>Myocardial infarction</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">18 (3.1)</td><td align="left">33 (2.8)</td><td align="left">29 (3.2)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.91 (0.51&#x02013;1.62)</td><td align="left">0.96 (0.53&#x02013;1.73)</td><td align="left">0.921</td><td align="left">1.01 (0.78&#x02013;1.30)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.91 (0.51&#x02013;1.62)</td><td align="left">1.01 (0.55&#x02013;1.85)</td><td align="left">0.913</td><td align="left">1.04 (0.80&#x02013;1.36)</td></tr><tr><td align="left" colspan="6"><bold>Hospitalization for unstable angina</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">55 (9.3)</td><td align="left">79 (6.8)</td><td align="left">54 (6.0)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.67 (0.47&#x02013;0.95)</td><td align="left">0.57 (0.39&#x02013;0.83)</td><td align="left">0.004</td><td align="left">0.75 (0.63&#x02013;0.90)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.72 (0.51&#x02013;1.02)</td><td align="left">0.65 (0.45&#x02013;0.96)</td><td align="left">0.036</td><td align="left">0.80 (0.67&#x02013;0.96)</td></tr><tr><td align="left" colspan="6"><bold>All-cause mortality</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">32 (5.4)</td><td align="left">32 (2.7)</td><td align="left">19 (2.1)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.45 (0.28&#x02013;0.75)</td><td align="left">0.33 (0.19&#x02013;0.59)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">0.56 (0.42&#x02013;0.74)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.46 (0.28&#x02013;0.75)</td><td align="left">0.35 (0.19&#x02013;0.63)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td><td align="left">0.57 (0.43&#x02013;0.76)</td></tr><tr><td align="left" colspan="6"><bold>CVD death</bold></td></tr><tr><td align="left">&#x02009;Events, <italic>n</italic> (%)</td><td align="left">18 (3.1)</td><td align="left">17 (1.5)</td><td align="left">10 (1.1)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;Model 1</td><td align="left">1.00</td><td align="left">0.46 (0.23&#x02013;0.90)</td><td align="left">0.34 (0.16&#x02013;0.75)</td><td align="left">0.006</td><td align="left">0.57 (0.39&#x02013;0.83)</td></tr><tr><td align="left">&#x02009;Model 2</td><td align="left">1.00</td><td align="left">0.47 (0.24&#x02013;0.93)</td><td align="left">0.36 (0.16&#x02013;0.79)</td><td align="left">0.010</td><td align="left">0.58 (0.39&#x02013;0.85)</td></tr></tbody></table><table-wrap-foot><p>Model 1. Adjusted for age, sex, region (non-Asian vs. Asian), CPAP allocation</p><p>Model 2. Further adjusted for history of coronary artery disease, history of cerebrovascular disease, history of hypertension, history of diabetes, baseline neck circumference, baseline antihypertensive agent, baseline statin or other lipid&#x02011;lowering agent, baseline antidiabetic oral medication, baseline insulin, baseline aspirin or other antithrombotic agent, and oxygen desaturation index</p><p><italic>CPAP</italic> indicates continuous positive airway pressure, <italic>CVD</italic> cardiovascular disease, <italic>SAVE</italic> Sleep Apnea Cardiovascular Endpoints</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Overall healthy lifestyle factors and secondary outcomes</title><p id="Par25">During a median follow-up of 3.7&#x000a0;years, 133 (5.0%) strokes, 80 (3.0%) myocardial infarctions, 188 (7.1%) hospitalizations for unstable angina, 83 (3.1%) cases of all-cause mortality, and 45 (1.7%) deaths from CVD were observed. Kaplan&#x02013;Meier curves show that participants with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had significantly lower cumulative incidence rates of stroke (log-rank <italic>P</italic>&#x02009;=&#x02009;0.0014, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B), hospitalization for unstable angina (log-rank <italic>P</italic>&#x02009;=&#x02009;0.0057, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D), all-cause mortality (log-rank <italic>P</italic>&#x02009;=&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E), and CVD death (log-rank <italic>P</italic>&#x02009;=&#x02009;0.0042, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>F). However, no association was observed for myocardial infarction (log-rank <italic>P</italic>&#x02009;=&#x02009;0.8710, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). Compared to participants without any healthy lifestyle factor, those with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had a 54% (HR 0.46, 95% CI 0.28&#x02013;0.74), 35% (HR 0.65, 95% CI 0.45&#x02013;0.96), 65% (HR 0.35, 95% CI 0.19&#x02013;0.63), and 64% (HR 0.36, 95% CI 0.16&#x02013;0.79) lower risk of stroke, hospitalization for unstable angina, all-cause mortality, and CVD death, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). No significant associations were observed for overall healthy lifestyle factors and risk of myocardial infarction (<italic>P</italic> for trend&#x02009;=&#x02009;0.913). Additionally, each one-point increase in overall healthy lifestyle factors score was significantly associated with reduced risks of stroke, hospitalization for unstable angina, all-cause mortality, and CVD death (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Meanwhile, compared to participants with no healthy lifestyle factors, those with&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors had an absolute risk reduction of 3.6% for stroke, 3.3% for hospitalization due to unstable angina, 3.3% for all-cause mortality, and 1.9% for CVD death (Additional file 1: Table S2). There was a dose-dependent risk reduction in composite cerebral events across each healthy lifestyle factor, but there was no association of overall healthy lifestyle factors and risks of TIA, composite cardiac events, and revascularization procedures (Additional file 1: Table S3).</p></sec><sec id="Sec11"><title>Subgroup analysis</title><p id="Par26">There was consistency in the associations between adherence to greater baseline healthy lifestyle factors and lower risk of composite cardiovascular events in most subgroups, those of age, region, sex, history of coronary artery disease, history of cerebrovascular disease, baseline BMI, and baseline AHI, ODI, and ESS score (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). There was a significant interaction between overall healthy lifestyle factors and history of coronary artery disease for the composite of cardiovascular events (<italic>P</italic> interaction&#x02009;=&#x02009;0.034). The association between adherence to overall baseline healthy lifestyle factors and reduced risk of composite cardiovascular events was significant only in those without a history of coronary artery disease. There was no significant interaction between overall healthy lifestyle factors and other subgroup variables (<italic>P</italic> interaction&#x02009;&#x0003e;&#x02009;0.05 for all) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>HRs (95% CIs) of composite cardiovascular events according to the overall healthy lifestyle factors in SAVE: key subgroups analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4"><bold>Numbers of overall healthy lifestyle factors</bold></th><th align="left"><bold><italic>P</italic></bold><bold> for interaction</bold></th></tr><tr><th align="left">0</th><th align="left">1</th><th align="left">&#x02265;&#x02009;2</th><th align="left"><italic>P</italic>trend</th><th align="left"/></tr></thead><tbody><tr><td align="left" colspan="5"><bold>Region</bold></td><td align="left">0.691</td></tr><tr><td align="left">&#x02009;Asian</td><td align="left">1.00</td><td align="left">0.78 (0.59&#x02013;1.03)</td><td align="left">0.63 (0.45&#x02013;0.86)</td><td align="left">0.004</td><td align="left"/></tr><tr><td align="left">&#x02009;Non-Asian</td><td align="left">1.00</td><td align="left">0.74 (0.49&#x02013;1.12)</td><td align="left">0.69 (0.44&#x02013;1.10)</td><td align="left">0.127</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Sex</bold></td><td align="left">0.592</td></tr><tr><td align="left">&#x02009;Male</td><td align="left">1.00</td><td align="left">0.75 (0.59&#x02013;0.97)</td><td align="left">0.66 (0.50&#x02013;0.87)</td><td align="left">0.004</td><td align="left"/></tr><tr><td align="left">&#x02009;Female</td><td align="left">1.00</td><td align="left">1.02 (0.46&#x02013;2.27)</td><td align="left">0.82 (0.33&#x02013;2.02)</td><td align="left">0.550</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Age, years</bold></td><td align="left">0.928</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;61</td><td align="left">1.00</td><td align="left">0.72 (0.51&#x02013;1.02)</td><td align="left">0.66 (0.45&#x02013;0.96)</td><td align="left">0.031</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;61</td><td align="left">1.00</td><td align="left">0.80 (0.58&#x02013;1.10)</td><td align="left">0.65 (0.46&#x02013;0.93)</td><td align="left">0.018</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>History of coronary artery disease</bold></td><td align="left">0.034</td></tr><tr><td align="left">&#x02009;No</td><td align="left">1.00</td><td align="left">0.73 (0.51&#x02013;1.06)</td><td align="left">0.48 (0.31&#x02013;0.75)</td><td align="left">0.001</td><td align="left"/></tr><tr><td align="left">&#x02009;Yes</td><td align="left">1.00</td><td align="left">0.78 (0.57&#x02013;1.05)</td><td align="left">0.77 (0.56&#x02013;1.07)</td><td align="left">0.141</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>History of cerebrovascular disease</bold></td><td align="left">0.078</td></tr><tr><td align="left">&#x02009;No</td><td align="left">1.00</td><td align="left">0.81 (0.58&#x02013;1.13)</td><td align="left">0.77 (0.54&#x02013;1.11)</td><td align="left">0.176</td><td align="left"/></tr><tr><td align="left">&#x02009;Yes</td><td align="left">1.00</td><td align="left">0.71 (0.51&#x02013;0.99)</td><td align="left">0.53 (0.36&#x02013;0.77)</td><td align="left">0.001</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Apnea&#x02013;hypopnea index</bold></td><td align="left">0.838</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;30 events/hour</td><td align="left">1.00</td><td align="left">0.73 (0.54&#x02013;0.98)</td><td align="left">0.68 (0.49&#x02013;0.94)</td><td align="left">0.025</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;30 events/hour</td><td align="left">1.00</td><td align="left">0.82 (0.57&#x02013;1.20)</td><td align="left">0.63 (0.41&#x02013;0.96)</td><td align="left">0.032</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Oxygen desaturation index (median)</bold></td><td align="left">0.483</td></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;24 events/hour</td><td align="left">1.00</td><td align="left">0.71 (0.51&#x02013;0.99)</td><td align="left">0.59 (0.41&#x02013;0.85)</td><td align="left">0.005</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;24 events/hour</td><td align="left">1.00</td><td align="left">0.83 (0.60&#x02013;1.16)</td><td align="left">0.74 (0.51&#x02013;1.07)</td><td align="left">0.109</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Epworth Sleepiness Scale score</bold></td><td align="left">0.356</td></tr><tr><td align="left">&#x02009;0&#x02013;9</td><td align="left">1.00</td><td align="left">0.85 (0.64&#x02013;1.12)</td><td align="left">0.68 (0.50&#x02013;0.93)</td><td align="left">0.015</td><td align="left"/></tr><tr><td align="left">&#x02009;10&#x02013;15</td><td align="left">1.00</td><td align="left">0.55 (0.36&#x02013;0.86)</td><td align="left">0.53 (0.33&#x02013;0.87)</td><td align="left">0.013</td><td align="left"/></tr><tr><td align="left" colspan="5"><bold>Baseline BMI, kg/m</bold><sup><bold>2</bold></sup></td><td align="left">0.070</td></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;30</td><td align="left">1.00</td><td align="left">0.88 (0.66&#x02013;1.19)</td><td align="left">0.79 (0.57&#x02013;1.09)</td><td align="left">0.144</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;30</td><td align="left">1.00</td><td align="left">0.62 (0.42&#x02013;0.91)</td><td align="left">0.47 (0.30&#x02013;0.74)</td><td align="left">0.001</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Adjusted for age, sex, region (non-Asian vs. Asian), history of coronary artery disease, history of cerebrovascular disease, history of hypertension, history of diabetes, baseline neck circumference, baseline antihypertensive agent, baseline statin or other lipid-lowering agent, baseline antidiabetic oral medication, baseline insulin, baseline aspirin or other antithrombotic agent, oxygen desaturation index, and CPAP allocation</p><p><italic>BMI</italic> indicates Body Mass Index, <italic>CPAP</italic> continuous positive airway pressure, <italic>SAVE</italic> Sleep Apnea Cardiovascular Endpoints</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Impact of overall healthy lifestyle factors on the effects of CPAP treatment</title><p id="Par27">Although there was a trend indicating a greater benefit of CPAP treatment in people with more baseline healthy lifestyle factors for the outcomes of myocardial infarction (<italic>P</italic> interaction&#x02009;=&#x02009;0.095) and all-cause mortality (<italic>P</italic> interaction&#x02009;=&#x02009;0.263), it did not reach statistical significance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). There was no evidence of significant heterogeneity in the effect of CPAP treatment by adherence to baseline healthy lifestyle factors on other outcomes including composite cardiovascular events (<italic>P</italic> interaction&#x02009;=&#x02009;0.921), stroke (<italic>P</italic> interaction&#x02009;=&#x02009;0.908), and hospitalization for unstable angina (<italic>P</italic> interaction&#x02009;=&#x02009;0.803) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In addition, we found no significant heterogeneity in the effect of good CPAP adherence compared with poor CPAP adherence on all outcomes by baseline healthy lifestyle factors (<italic>P</italic> interaction&#x02009;&#x02265;&#x02009;0.621 for all) (Additional file 1: Figure S4).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>HRs (95% CIs) of CPAP treatment effect according to the overall healthy lifestyle factors in SAVE&#x000a0;CPAP indicates continuous positive airway pressure; SAVE Sleep Apnea Cardiovascular Endpoints</p></caption><graphic xlink:href="12916_2025_4279_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par28">This analysis of the SAVE study cohort involving 2659 participants with moderate-to-severe OSA and established coronary artery disease and/or cerebrovascular disease has shown that adherence to overall baseline healthy lifestyle factors of never smoking, moderate to vigorous physical activity, low to moderate alcohol consumption, and ideal WHR was associated with a significantly reduced risk of composite and individual cardiovascular events. The associations were consistent across subgroups defined by age, region, sex, history of coronary artery disease or cerebrovascular disease, baseline BMI, and OSA severity, including AHI, ODI, and ESS. We found a trend suggesting that greater benefits from CPAP treatment occur in those with a healthier baseline lifestyle for the outcomes of myocardial infarction and all-cause mortality; however, it did not reach statistical significance.</p><p id="Par29">OSA is highly prevalent in patients with CVD, exacerbating the severity of their condition and elevating the risk of recurrent CVD events [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Unhealthy lifestyle factors such as low physical activity, smoking, poor dietary habits, and obesity are common risk factors for both OSA and CVD [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. In the present study, we found that two-thirds (66.2%) of OSA patients had 0 or 1 healthy lifestyle factor, indicating that unhealthy lifestyle habits are more prevalent among OSA patients with existing CVD, which was in line with a previous study [<xref ref-type="bibr" rid="CR27">27</xref>]. Previous studies indicate that weight loss and lifestyle intervention can reduce OSA severity and improve health-related quality of life [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover, several large observational studies have shown that adherence to overall healthy lifestyle behaviors is associated with reduced risks of CVD in general populations and in those with diabetes mellitus [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. These data are compelling enough to support similar associations in those with OSA, especially in those with established CVD. To our knowledge, this is the first study to assess overall baseline healthy lifestyle factors and recurrent cardiovascular events in high-risk OSA patients with existing CVD. We found that compared to participants who reported no healthy lifestyle factors, reporting&#x02009;&#x02265;&#x02009;2 healthy lifestyle factors was significantly associated with a lower risk of composite cardiovascular events, stroke, hospitalization for unstable angina, all-cause mortality, and CVD death. We also found a dose-dependent relationship between healthy lifestyle factors and cardiovascular outcomes, which is consistent with earlier studies [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par30">Evidence for overall healthy lifestyle factors and lower risk of CVD has been established in general populations with an overall low risk of CVD [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. For example, the China Kadoorie Biobank study of 461,211 participants found that adherence to an overall healthy lifestyle characterized by never smoking, consuming alcohol lightly or moderately, being physically active, consuming a healthy diet, and maintaining a healthy weight without central adiposity was associated with low ischemic CVD risk during a mean 7.2&#x000a0;years of follow-up [<xref ref-type="bibr" rid="CR15">15</xref>]. The Health Professionals Follow-up Study and the Nurses&#x02019; Health data have also shown that adopting a lifestyle with minimal risk factors, such as not smoking, having a normal weight, engaging in moderate activity, drinking alcohol in moderation, and following a healthy diet, was associated with a lower risk of stroke [<xref ref-type="bibr" rid="CR28">28</xref>]. Our finding confirms and ratifies this knowledge by showing an association between adherence to overall baseline healthy lifestyle factors and lower risk of recurrent CVD in an increasingly important patient population involving concomitant OSA and CVD.</p><p id="Par31">The associations of overall healthy lifestyle factors and cardiovascular events differed between stroke and myocardial infarction, in being significant only in those with pre-existing cerebrovascular CVD. One possible explanation is differing statistical power as the rate of stroke (5.0%) was higher than that of myocardial infarction (3.0%) in the SAVE cohort, consistent with literature indicating that the risk of stroke is greater than myocardial infarction in adults with OSA [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Observational follow-up time is also relevant, being a mean of 3.7&#x000a0;years in our study compared to over 10&#x000a0;years in a population-based prospective cohort study [<xref ref-type="bibr" rid="CR31">31</xref>]. It is also plausible that there are differences in the underlying pathophysiological mechanisms of the component cardiovascular event types that are affected differentially by the factors that we assessed.</p><p id="Par32">Previous studies also indicate that the risk of CVD increases with the severity of OSA, particularly in relation to higher AHI and ESS scores [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. In our analysis, the association of adherence to overall baseline healthy lifestyle factors and decreased risk of composite cardiovascular events was consistent across OSA severity, including AHI, ODI, and ESS, indicating that our findings are applicable across individuals with different degrees of OSA severity.</p><p id="Par33">We found a trend of greater benefit from CPAP treatment in those with better adherence to healthy lifestyle factors for the outcomes of myocardial infarction and all-cause mortality, although the trend did not reach significance. It is possible that we were underpowered to detect a statistically significant treatment effect, and future studies with larger sample sizes are warranted to validate our findings. A secondary analysis of the SAVE study indicated that CPAP treatment positively influences physical activity levels [<xref ref-type="bibr" rid="CR34">34</xref>]. When considered alongside our findings, this suggests that long-term CPAP use may contribute to reduced recurrence of cardiovascular events by promoting increased physical activity, although the primary findings of the SAVE study showed that CPAP plus usual care over a median follow-up of 3.7&#x000a0;years did not significantly reduce recurrent cardiovascular events compared to usual care alone [<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, we found no differences in any outcomes when comparing good CPAP adherence with poor adherence across the overall baseline healthy lifestyle factors. Although a recent individual participant data meta-analysis of 4186 OSA participants, including the SAVE cohort, indicated that good adherence to CPAP is associated with reduced recurrent CVD outcomes [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec14"><title>Strengths and limitations</title><p id="Par34">A key strength of our study was the opportunity to use data from the SAVE study, the largest randomized evaluation of the effects of CPAP in OSA participants with co-occurring CVD who were well characterized, systematically assessed, and followed up in a range of health care settings, providing reliability and generalizability to the findings. Our study is also the first to investigate the association of overall healthy lifestyle factors and CVD in unique and high-risk population patients with OSA and established CVD. Our findings suggest that lifestyle modification could offer independent and additive benefits beyond CPAP therapy, which may be especially important for patients with suboptimal CPAP adherence or limited response. There are limitations such as the lack of dietary information, preventing us from including a high-quality diet as a component of overall healthy lifestyle factors; a high-quality diet is acknowledged as an important lifestyle behavior linked to a lower CVD [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. The self-reported nature of the health behaviors data that were collected in SAVE is also a limitation; unfortunately, objective measurements of physical activity were not available. Another issue is that SAVE participants had moderate to severe OSA with existing CVD. Thus, our results may not be generalizable to adults with mild OSA or the broader OSA population without CVD. Finally, the possibility of residual confounding cannot be fully eliminated in a post-hoc study, although several important potential confounders were controlled in the multivariable-adjusted models.</p></sec><sec id="Sec15"><title>Conclusions</title><p id="Par35">Our analysis of the SAVE study indicates that adherence to baseline healthy lifestyle factors in OSA patients with CVD is significantly associated with lower risk of composite cardiovascular events, stroke, hospitalization for unstable angina, all-cause mortality, and CVD death. Moreover, these associations were robust and consistent across baseline demographic characteristics and OSA severity levels. A trend was found showing greater CPAP treatment benefit in those with more baseline healthy lifestyle for the outcomes of myocardial infarction and all-cause mortality, although it did not reach statistical significance. Our findings emphasize the importance of patients with OSA and established CVD adopting a healthy lifestyle to reduce the risk of recurrent CVD events. These insights may help inform more comprehensive risk-reduction strategies in clinical practice.</p></sec><sec id="Sec16" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4279_MOESM1_ESM.docx"><caption><p>Additional file 1: Figure S1. Directed acyclic graph depicting the rationale for confounder selection. Figure S2. Patients&#x02019; flowchart. Figure S3. The distribution of overall baseline healthy lifestyle factors. Figure S4. HRsof good CPAP adherence effect according to the overall healthy lifestyle factors in SAVE. Table S1. HRsof primary outcome according to individual healthy lifestyle factors in SAVE. Table S2. Absolute risk reductions of primary and secondary outcomes by baseline healthy lifestyle factors. Table S3. [other secondary outcomes according to the overall healthy lifestyle factors in SAVE]</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AHI</term><def><p id="Par5">Apnea&#x02013;hypopnea index</p></def></def-item><def-item><term>BP</term><def><p id="Par6">Blood pressure</p></def></def-item><def-item><term>BMI</term><def><p id="Par7">Body-mass index</p></def></def-item><def-item><term>CVD</term><def><p id="Par8">Cardiovascular disease</p></def></def-item><def-item><term>CPAP</term><def><p id="Par9">Continuous positive airway pressure</p></def></def-item><def-item><term>ESS</term><def><p id="Par10">Epworth sleepiness scale</p></def></def-item><def-item><term>OSA</term><def><p id="Par11">Obstructive sleep apnea</p></def></def-item><def-item><term>ODI</term><def><p id="Par12">Oxygen desaturation index</p></def></def-item><def-item><term>SAVE</term><def><p id="Par13">Sleep Apnea Cardiovascular Endpoints</p></def></def-item><def-item><term>TIA</term><def><p id="Par14">Transient ischemic attack</p></def></def-item><def-item><term>WHR</term><def><p id="Par15">Waist/hip ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Shoujiang You and Danni Zheng contributed equally to this study.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the SAVE investigators for their contributions.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>SY, DZ and CSA contributed to the concept and rationale for the study; SY, DZ, and QL conducted statistical analyses; SY and DZ were responsible for the first draft; KAL, FB, YL, QO, RC, CL, YC, GL for data collection/management; CSA, KAL, RDM, MT and XW for revisions. All authors read and approved the final manuscript.
</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The SAVE trial was supported by project grants (1006501 (2011&#x02013;2015) and 1060078 (2014&#x02013;2016)) from the National Health and Medical Research Council (NHMRC) of Australia and by Respironics Sleep and Respiratory Research Foundation and Philips Respironics. Supplementary trial funding was provided by Fisher &#x00026; Paykel Healthcare, the Australasian Sleep Trials Network (enabling grant 343020 from the NHMRC), the Spanish Respiratory Society (grant 105-2011), and Fondo de Investigaciones Sanitarias (grant 13/02053). In-kind donations were provided by Respironics for CPAP equipment and by ResMed for sleep apnea diagnostic devices.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par36">Local institutional review boards or independent ethics committees at recruiting sites approved the protocol, and all participants provided written informed consent.</p></notes><notes id="FPar2"><title>Consent for publication&#x000a0;</title><p id="Par37">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">Dr. You holds the National Natural Science Foundation of China (82471226), Discipline Construction Program of the Second Affiliated Hospital of Soochow University (XKTJ-RC202412), Jiangsu Provincial Medical Key Discipline (ZDXK202217) and the 6th Jiangsu Province 333 High Level Talents Training Project. Dr. Wang holds an investigator grant from the National Health and Medical Research Council (NHMRC) of Australia; Dr. Ferran Barb&#x000e9; is supported by the ICREA Academia program from Generalitat de Catalunya. Dr. Anderson holds a NHMRC Senior Investigator Fellowship and reports grant funding from NHMRC, Penumbra, and Takeda China. The other authors have nothing to disclose.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeghiazarians</surname><given-names>Y</given-names></name><name><surname>Jneid</surname><given-names>H</given-names></name><name><surname>Tietjens</surname><given-names>JR</given-names></name><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>El-Sherif</surname><given-names>N</given-names></name><etal/></person-group><article-title>Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>e56</fpage><lpage>e67</lpage><pub-id pub-id-type="pmid">34148375</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144:e56&#x02013;67.<pub-id pub-id-type="pmid">34148375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>DJ</given-names></name><name><surname>Punjabi</surname><given-names>NM</given-names></name></person-group><article-title>Diagnosis and management of obstructive sleep apnea: a review</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1389</fpage><lpage>1400</lpage><pub-id pub-id-type="pmid">32286648</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. JAMA. 2020;323:1389&#x02013;400.<pub-id pub-id-type="pmid">32286648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Sethi</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>HH</given-names></name><name><surname>Hein</surname><given-names>T</given-names></name><name><surname>Jim</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>2008</fpage><lpage>2017</lpage><pub-id pub-id-type="pmid">27178625</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lee CH, Sethi R, Li R, Ho HH, Hein T, Jim MH, et al. Obstructive sleep apnea and cardiovascular events after percutaneous coronary intervention. Circulation. 2016;133:2008&#x02013;17.<pub-id pub-id-type="pmid">27178625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>A</given-names></name><name><surname>Camilo</surname><given-names>M</given-names></name><name><surname>Korostovtseva</surname><given-names>L</given-names></name><name><surname>Haynes</surname><given-names>AG</given-names></name><name><surname>Brill</surname><given-names>AK</given-names></name><name><surname>Horvath</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prevalence of sleep-disordered breathing after stroke and TIA: a meta-analysis</article-title><source>Neurology</source><year>2019</year><volume>92</volume><fpage>e648</fpage><lpage>e654</lpage><pub-id pub-id-type="pmid">30635478</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Seiler A, Camilo M, Korostovtseva L, Haynes AG, Brill AK, Horvath T, et al. Prevalence of sleep-disordered breathing after stroke and TIA: a meta-analysis. Neurology. 2019;92:e648&#x02013;54.<pub-id pub-id-type="pmid">30635478</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Javaheri</surname><given-names>S</given-names></name><name><surname>Barbe</surname><given-names>F</given-names></name><name><surname>Campos-Rodriguez</surname><given-names>F</given-names></name><name><surname>Dempsey</surname><given-names>JA</given-names></name><name><surname>Khayat</surname><given-names>R</given-names></name><name><surname>Javaheri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sleep apnea: types, mechanisms, and clinical cardiovascular consequences</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>69</volume><fpage>841</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">28209226</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841&#x02013;58.<pub-id pub-id-type="pmid">28209226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Valham</surname><given-names>F</given-names></name><name><surname>Mooe</surname><given-names>T</given-names></name><name><surname>Rabben</surname><given-names>T</given-names></name><name><surname>Stenlund</surname><given-names>H</given-names></name><name><surname>Wiklund</surname><given-names>U</given-names></name><name><surname>Franklin</surname><given-names>KA</given-names></name></person-group><article-title>Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>955</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">18697817</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Valham F, Mooe T, Rabben T, Stenlund H, Wiklund U, Franklin KA. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation. 2008;118:955&#x02013;60.<pub-id pub-id-type="pmid">18697817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Shafie-Khorassani</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Chervin</surname><given-names>RD</given-names></name><name><surname>Case</surname><given-names>E</given-names></name><name><surname>Morgenstern</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Sleep-disordered breathing is associated with recurrent ischemic stroke</article-title><source>Stroke</source><year>2019</year><volume>50</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">30744545</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Brown DL, Shafie-Khorassani F, Kim S, Chervin RD, Case E, Morgenstern LB, et al. Sleep-disordered breathing is associated with recurrent ischemic stroke. Stroke. 2019;50:571&#x02013;6.<pub-id pub-id-type="pmid">30744545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Hao</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of obstructive sleep apnoea with cardiovascular events in women and men with acute coronary syndrome</article-title><source>Eur Respir J</source><year>2023</year><volume>61</volume><fpage>2201110</fpage><pub-id pub-id-type="pmid">36104289</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang X, Fan J, Guo R, Hao W, Gong W, Yan Y, et al. Association of obstructive sleep apnoea with cardiovascular events in women and men with acute coronary syndrome. Eur Respir J. 2023;61:2201110.<pub-id pub-id-type="pmid">36104289</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Drager</surname><given-names>LF</given-names></name><name><surname>Togeiro</surname><given-names>SM</given-names></name><name><surname>Polotsky</surname><given-names>VY</given-names></name><name><surname>Lorenzi-Filho</surname><given-names>G</given-names></name></person-group><article-title>Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23770180</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62:569&#x02013;76.<pub-id pub-id-type="pmid">23770180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrosielski</surname><given-names>DA</given-names></name><name><surname>Papandreou</surname><given-names>C</given-names></name><name><surname>Patil</surname><given-names>SP</given-names></name><name><surname>Salas-Salvad&#x000f3;</surname><given-names>J</given-names></name></person-group><article-title>Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk</article-title><source>Eur Respir Rev</source><year>2017</year><volume>26</volume><fpage>160110</fpage><pub-id pub-id-type="pmid">28659501</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Dobrosielski DA, Papandreou C, Patil SP, Salas-Salvad&#x000f3; J. Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk. Eur Respir Rev. 2017;26:160110.<pub-id pub-id-type="pmid">28659501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><fpage>3374</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">34333624</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Han Y, Hu Y, Yu C, Guo Y, Pei P, Yang L, et al. Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study. Eur Heart J. 2021;42:3374&#x02013;84.<pub-id pub-id-type="pmid">34333624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro-Barrera</surname><given-names>A</given-names></name><name><surname>Amaro-Gahete</surname><given-names>FJ</given-names></name><name><surname>Guill&#x000e9;n-Riquelme</surname><given-names>A</given-names></name><name><surname>Jurado-Fasoli</surname><given-names>L</given-names></name><name><surname>S&#x000e1;ez-Roca</surname><given-names>G</given-names></name><name><surname>Mart&#x000ed;n-Carrasco</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial</article-title><source>JAMA Netw Open</source><year>2022</year><volume>5</volume><fpage>e228212</fpage><pub-id pub-id-type="pmid">35452108</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Carneiro-Barrera A, Amaro-Gahete FJ, Guill&#x000e9;n-Riquelme A, Jurado-Fasoli L, S&#x000e1;ez-Roca G, Mart&#x000ed;n-Carrasco C, et al. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity: the INTERAPNEA randomized clinical trial. JAMA Netw Open. 2022;5: e228212.<pub-id pub-id-type="pmid">35452108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Tuomilehto</surname><given-names>HP</given-names></name><name><surname>Sepp&#x000e4;</surname><given-names>JM</given-names></name><name><surname>Partinen</surname><given-names>MM</given-names></name><name><surname>Peltonen</surname><given-names>M</given-names></name><name><surname>Gylling</surname><given-names>H</given-names></name><name><surname>Tuomilehto</surname><given-names>JO</given-names></name><etal/></person-group><article-title>Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea</article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>179</volume><fpage>320</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19011153</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tuomilehto HP, Sepp&#x000e4; JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JO, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 2009;179:320&#x02013;7.<pub-id pub-id-type="pmid">19011153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuna</surname><given-names>ST</given-names></name><name><surname>Reboussin</surname><given-names>DM</given-names></name><name><surname>Strotmeyer</surname><given-names>ES</given-names></name><name><surname>Millman</surname><given-names>RP</given-names></name><name><surname>Zammit</surname><given-names>G</given-names></name><name><surname>Walkup</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study</article-title><source>Am J Respir Crit Care Med</source><year>2021</year><volume>203</volume><fpage>221</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32721163</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kuna ST, Reboussin DM, Strotmeyer ES, Millman RP, Zammit G, Walkup MP, et al. Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med. 2021;203:221&#x02013;9.<pub-id pub-id-type="pmid">32721163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Bian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Adherence to healthy lifestyle and cardiovascular diseases in the Chinese population</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>69</volume><fpage>1116</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">28254173</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Lv J, Yu C, Guo Y, Bian Z, Yang L, Chen Y, et al. Adherence to healthy lifestyle and cardiovascular diseases in the Chinese population. J Am Coll Cardiol. 2017;69:1116&#x02013;25.<pub-id pub-id-type="pmid">28254173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Schoufour</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>DD</given-names></name><name><surname>Dhana</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>l6669</fpage><pub-id pub-id-type="pmid">31915124</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ. 2020;368: l6669.<pub-id pub-id-type="pmid">31915124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zong</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus</article-title><source>J Am Coll Cardiol</source><year>2018</year><volume>71</volume><fpage>2867</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">29929608</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Liu G, Li Y, Hu Y, Zong G, Li S, Rimm EB, et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus. J Am Coll Cardiol. 2018;71:2867&#x02013;76.<pub-id pub-id-type="pmid">29929608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ideal Cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes</article-title><source>JAMA Cardiol</source><year>2019</year><volume>4</volume><fpage>874</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">31365039</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Wang T, Lu J, Su Q, Chen Y, Bi Y, Mu Y, et al. Ideal Cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 2019;4:874&#x02013;83.<pub-id pub-id-type="pmid">31365039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>McEvoy</surname><given-names>RD</given-names></name><name><surname>Antic</surname><given-names>NA</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>CPAP for prevention of cardiovascular events in obstructive sleep apnea</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">27571048</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919&#x02013;31.<pub-id pub-id-type="pmid">27571048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Antic</surname><given-names>NA</given-names></name><name><surname>Heeley</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>CS</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><etal/></person-group><article-title>The Sleep Apnea cardioVascular Endpoints (SAVE) trial: rationale, ethics, design, and progress</article-title><source>Sleep</source><year>2015</year><volume>38</volume><fpage>1247</fpage><lpage>1257</lpage><pub-id pub-id-type="pmid">25669180</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Antic NA, Heeley E, Anderson CS, Luo Y, Wang J, Neal B, et al. The Sleep Apnea cardioVascular Endpoints (SAVE) trial: rationale, ethics, design, and progress. Sleep. 2015;38:1247&#x02013;57.<pub-id pub-id-type="pmid">25669180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><name><surname>Allen</surname><given-names>NB</given-names></name><name><surname>Anderson</surname><given-names>CAM</given-names></name><name><surname>Black</surname><given-names>T</given-names></name><name><surname>Brewer</surname><given-names>LC</given-names></name><name><surname>Foraker</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Life&#x02019;s essential 8: updating and enhancing the American Heart Association&#x02019;s construct of cardiovascular health: a presidential advisory from the American Heart Association</article-title><source>Circulation</source><year>2022</year><volume>146</volume><fpage>e18</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">35766027</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life&#x02019;s essential 8: updating and enhancing the American Heart Association&#x02019;s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146:e18-43.<pub-id pub-id-type="pmid">35766027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Blomster</surname><given-names>JI</given-names></name><name><surname>Chow</surname><given-names>CK</given-names></name><name><surname>Zoungas</surname><given-names>S</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><etal/></person-group><article-title>The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>1008</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23675676</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Blomster JI, Chow CK, Zoungas S, Woodward M, Patel A, Poulter NR, et al. The influence of physical activity on vascular complications and mortality in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:1008&#x02013;12.<pub-id pub-id-type="pmid">23675676</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="book"><person-group person-group-type="author"><collab>Royal College of Physicians</collab></person-group><source>The medical consequences of alcohol abuse, a great and growing evil</source><year>1987</year><publisher-loc>London</publisher-loc><publisher-name>Tavistock Publications Ltd</publisher-name></element-citation><mixed-citation id="mc-CR23" publication-type="book">Royal College of Physicians. The medical consequences of alcohol abuse, a great and growing evil. London: Tavistock Publications Ltd; 1987.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Blomster</surname><given-names>JI</given-names></name><name><surname>Zoungas</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chow</surname><given-names>CK</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><etal/></person-group><article-title>The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>1353</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">24578358</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes Care. 2014;37:1353&#x02013;9.<pub-id pub-id-type="pmid">24578358</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JD</given-names></name><name><surname>Chiou</surname><given-names>WK</given-names></name><name><surname>Weng</surname><given-names>HF</given-names></name><name><surname>Fang</surname><given-names>JT</given-names></name><name><surname>Liu</surname><given-names>TH</given-names></name></person-group><article-title>Application of three-dimensional body scanner: observation of prevalence of metabolic syndrome</article-title><source>Clin Nutr</source><year>2004</year><volume>23</volume><fpage>1313</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15556253</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lin JD, Chiou WK, Weng HF, Fang JT, Liu TH. Application of three-dimensional body scanner: observation of prevalence of metabolic syndrome. Clin Nutr. 2004;23:1313&#x02013;23.<pub-id pub-id-type="pmid">15556253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">World Health Organisation. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8&#x02013;11 December 2008, World Health Organization. 2011. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en/">http://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en/</ext-link>. Accessed Nov 2014</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Zapater</surname><given-names>A</given-names></name><name><surname>S&#x000e1;nchez-de-la-Torre</surname><given-names>M</given-names></name><name><surname>Ben&#x000ed;tez</surname><given-names>ID</given-names></name><name><surname>Targa</surname><given-names>A</given-names></name><name><surname>Bertran</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>G</given-names></name><etal/></person-group><article-title>The effect of sleep apnea on cardiovascular events in different acute coronary syndrome phenotypes</article-title><source>Am J Respir Crit Care Med</source><year>2020</year><volume>202</volume><fpage>1698</fpage><lpage>1706</lpage><pub-id pub-id-type="pmid">32648771</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zapater A, S&#x000e1;nchez-de-la-Torre M, Ben&#x000ed;tez ID, Targa A, Bertran S, Torres G, et al. The effect of sleep apnea on cardiovascular events in different acute coronary syndrome phenotypes. Am J Respir Crit Care Med. 2020;202:1698&#x02013;706.<pub-id pub-id-type="pmid">32648771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Rexrode</surname><given-names>KM</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Logroscino</surname><given-names>G</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Primary prevention of stroke by healthy lifestyle</article-title><source>Circulation</source><year>2008</year><volume>118</volume><fpage>947</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">18697819</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation. 2008;118:947&#x02013;54.<pub-id pub-id-type="pmid">18697819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Chomistek</surname><given-names>AK</given-names></name><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Eliassen</surname><given-names>AH</given-names></name><name><surname>Mukamal</surname><given-names>KJ</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Healthy lifestyle in the primordial prevention of cardiovascular disease among young women</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">25572509</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Chomistek AK, Chiuve SE, Eliassen AH, Mukamal KJ, Willett WC, Rimm EB. Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol. 2015;65:43&#x02013;51.<pub-id pub-id-type="pmid">25572509</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Azarbarzin</surname><given-names>A</given-names></name><name><surname>Peker</surname><given-names>Y</given-names></name></person-group><article-title>Obstructive sleep apnoea heterogeneity and cardiovascular disease</article-title><source>Nat Rev Cardiol</source><year>2023</year><volume>20</volume><fpage>560</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">36899115</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Redline S, Azarbarzin A, Peker Y. Obstructive sleep apnoea heterogeneity and cardiovascular disease. Nat Rev Cardiol. 2023;20:560&#x02013;73.<pub-id pub-id-type="pmid">36899115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Akesson</surname><given-names>A</given-names></name><name><surname>Larsson</surname><given-names>SC</given-names></name><name><surname>Discacciati</surname><given-names>A</given-names></name><name><surname>Wolk</surname><given-names>A</given-names></name></person-group><article-title>Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><fpage>1299</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">25257629</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Akesson A, Larsson SC, Discacciati A, Wolk A. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol. 2014;64:1299&#x02013;306.<pub-id pub-id-type="pmid">25257629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>DJ</given-names></name><name><surname>Yenokyan</surname><given-names>G</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>O'Connor</surname><given-names>GT</given-names></name><name><surname>Punjabi</surname><given-names>NM</given-names></name><name><surname>Quan</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">20625114</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gottlieb DJ, Yenokyan G, Newman AB, O&#x02019;Connor GT, Punjabi NM, Quan SF, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352&#x02013;60.<pub-id pub-id-type="pmid">20625114</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzotti</surname><given-names>DR</given-names></name><name><surname>Keenan</surname><given-names>BT</given-names></name><name><surname>Lim</surname><given-names>DC</given-names></name><name><surname>Gottlieb</surname><given-names>DJ</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Pack</surname><given-names>AI</given-names></name></person-group><article-title>Symptom subtypes of obstructive sleep apnea predict incidence of cardiovascular outcomes</article-title><source>Am J Respir Crit Care Med</source><year>2019</year><volume>200</volume><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">30764637</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Mazzotti DR, Keenan BT, Lim DC, Gottlieb DJ, Kim J, Pack AI. Symptom subtypes of obstructive sleep apnea predict incidence of cardiovascular outcomes. Am J Respir Crit Care Med. 2019;200:493&#x02013;506.<pub-id pub-id-type="pmid">30764637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>D</given-names></name><name><surname>Loffler</surname><given-names>KA</given-names></name><name><surname>Buman</surname><given-names>MP</given-names></name><name><surname>Dunstan</surname><given-names>DW</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Lorenzi-Filho</surname><given-names>G</given-names></name><etal/></person-group><article-title>CPAP increases physical activity in obstructive sleep apnea with cardiovascular disease</article-title><source>J Clin Sleep Med</source><year>2021</year><volume>17</volume><fpage>141</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32951632</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Stevens D, Loffler KA, Buman MP, Dunstan DW, Luo Y, Lorenzi-Filho G, et al. CPAP increases physical activity in obstructive sleep apnea with cardiovascular disease. J Clin Sleep Med. 2021;17:141&#x02013;8.<pub-id pub-id-type="pmid">32951632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez-de-la-Torre</surname><given-names>M</given-names></name><name><surname>Gracia-Lavedan</surname><given-names>E</given-names></name><name><surname>Benitez</surname><given-names>ID</given-names></name><name><surname>S&#x000e1;nchez-de-la-Torre</surname><given-names>A</given-names></name><name><surname>Moncus&#x000ed;-Moix</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>G</given-names></name><etal/></person-group><article-title>Adherence to CPAP treatment and the risk of recurrent cardiovascular events: a meta-analysis</article-title><source>JAMA</source><year>2023</year><volume>330</volume><fpage>1255</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">37787793</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">S&#x000e1;nchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, S&#x000e1;nchez-de-la-Torre A, Moncus&#x000ed;-Moix A, Torres G, et al. Adherence to CPAP treatment and the risk of recurrent cardiovascular events: a meta-analysis. JAMA. 2023;330:1255&#x02013;65.<pub-id pub-id-type="pmid">37787793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Mente</surname><given-names>A</given-names></name><name><surname>Dehghan</surname><given-names>M</given-names></name><name><surname>Rangarajan</surname><given-names>S</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Dagenais</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diet, cardiovascular disease, and mortality in 80 countries</article-title><source>Eur Heart J</source><year>2023</year><volume>44</volume><fpage>2560</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">37414411</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Mente A, Dehghan M, Rangarajan S, O&#x02019;Donnell M, Hu W, Dagenais G, et al. Diet, cardiovascular disease, and mortality in 80 countries. Eur Heart J. 2023;44:2560&#x02013;79.<pub-id pub-id-type="pmid">37414411</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Baden</surname><given-names>MY</given-names></name><name><surname>Bhupathiraju</surname><given-names>SN</given-names></name><name><surname>Wang</surname><given-names>DD</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Association between healthy eating patterns and risk of cardiovascular disease</article-title><source>JAMA Intern Med</source><year>2020</year><volume>180</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">32539102</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Shan Z, Li Y, Baden MY, Bhupathiraju SN, Wang DD, Sun Q, et al. Association between healthy eating patterns and risk of cardiovascular disease. JAMA Intern Med. 2020;180:1090&#x02013;100.<pub-id pub-id-type="pmid">32539102</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>